RealTime Dynamix™: AS and Nr-AxSpA Q2 2017 Spotlight

US rheumatologists highlight difficulties in axial spondyloarthropathy diagnosis and timely referrals, according to RealTime Dynamix: Ankylosing Spondylitis and Non Radiographic Axial Spondyloarthropathy Q2. Despite the possibility of a large undiagnosed population of patients with AS or nr-axSpA, when patients are treated, US rheumatologists report high satisfaction with the existing TNF-inhibitors, such as AbbVie’s Humira, Amgen’s Enbrel, and Janssen’s Remicade,

Click the button below to view highlights from this quarter 2 report:

Download Report Spotlight

2017-10-17T19:45:34+00:00